The CALM study, led by Melissa Kimber of McMaster University and Flavia Vieira of the University of Calgary together with a large multidisciplinary team spanning six Canadian sites, is designed to reframe how scientists think about co-occurring mental disorders. Rather than treating diagnostic overlap as a statistical nuisance, the investigators want to operationalize multimorbidity as a dynamic, multilevel prognostic construct, one that integrates diagnostic burden, developmental trajectories, and underlying biological and psychosocial mechanisms within a single research framework. The team argues that this shift is overdue: multimorbidity complicates clinical decision-making, predicts poorer functional outcomes, and drives higher service utilization across the lifespan, so understanding it in adolescence and young adulthood could pay dividends for decades.

The architecture of the study is what sets it apart. CALM is a multi-site, prospective longitudinal master observational trial, a design borrowed from other areas of medicine that provides a harmonized infrastructure for real-world clinical cohorts while simultaneously embedding randomized controlled trials. In practice, this means the cohort is not just a passive registry of patients followed over time. It is a living platform onto which intervention studies can be grafted, allowing researchers to test treatments in a population that has already been deeply characterized. The trial is registered as NCT07699159 and is actively recruiting across six sites in Canada, including centres in Toronto, Hamilton, Ottawa, and Calgary.

Enrollment targets are substantial. The core of the study is a harmonized Light protocol that aims to recruit approximately 1,600 young people aged 11 to 24 years. Since its launch in March 2025, the study has already enrolled 832 youth and 446 caregivers into the Light protocol, a pace that suggests strong demand for a research model that reflects the complexity young people actually experience. Light protocol data are captured at nine timepoints over 42 months, a dense sampling schedule designed to capture the fluctuating symptom profiles that characterize adolescence and the transition to adulthood.

The Light protocol is deliberately lean but broad. It includes youth- and caregiver-reported measures covering core clinical, functional, and contextual domains, alongside point-of-care digital and biological data collection for genomic and proteomic analyses. The diagnostic backbone is the Diagnostic Assessment for the Health Spectrum, a semi-structured interview administered by trained research staff that yields both categorical diagnoses aligned with the Diagnostic and Statistical Manual of Mental Disorders and dimensional diagnostic spectra. This dual output is technically significant: categorical diagnoses are what clinicians use in practice, while dimensional spectra allow researchers to model symptom severity continuously, which is often better suited to studying conditions that overlap and blend into one another.

For a subset of participants, the study goes much deeper. Approximately 600 young people are enrolled into the Deep protocol, which adds expanded psychosocial, neurocognitive, and neuroimaging assessments collected over six months. The neuroimaging component draws on techniques such as resting-state functional MRI, diffusion-weighted imaging, and arterial spin labeling, methods that probe brain connectivity, white matter structure, and cerebral blood flow respectively. By layering these mechanistic measurements onto the longitudinal clinical data, the researchers hope to enable translational analyses that connect brain biology to the lived trajectory of multimorbidity, potentially identifying markers that predict which young people will deteriorate and which will recover.

The embedded trial capability is already being used. Three randomized controlled trials addressing sleep, stigma, and youth with complex mental health needs are at varying stages of integration within the CALM platform. One of these involves Narrative Enhancement Cognitive Therapy for Youth, an intervention targeting the internalized stigma that so often accompanies psychiatric diagnosis in adolescence. This trials-within-cohorts approach, sometimes abbreviated TwiCs, offers practical advantages: participants in the cohort can be screened efficiently for trial eligibility, randomized trials can draw on a pre-characterized population, and the observational data continue flowing regardless of whether an individual joins an embedded experiment. The result is a research engine in which each new trial inherits the full phenotypic depth of the parent cohort.

The study also reflects a growing recognition that youth themselves must shape the research that concerns them. The protocol acknowledges dedicated Youth Advisory and Family Advisory Groups whose members have contributed to the design and conduct of the study, and the research team spans disciplines from psychiatry and psychology to radiology, nursing, biostatistics, and neuroinformatics. Ethical oversight was provided by Clinical Trials Ontario for the Ontario sites and by the Conjoint Health Research Ethics Board at the University of Calgary for the Alberta site, with informed consent obtained before any data collection and procedures compliant with the Declaration of Helsinki. The work is supported by the Ontario Brain Institute, along with foundation and institutional partners including the Waverley House Foundation, the Alberta Children’s Hospital Foundation, and The Molson Foundation.

Why does this matter beyond the research community? Roughly half of lifetime mental disorders begin by the mid-teen years, and young people who present with multiple conditions are among the highest users of emergency departments, inpatient units, and community services. Single-disorder trials simply cannot answer the questions these families ask: which treatment should come first when depression, anxiety, and ADHD co-occur, and how do sleep, stigma, and family context modify the answer? By building a cohort that mirrors clinical reality, CALM aims to generate evidence that maps onto the patients clinicians actually see. If the master observational trial model proves viable in child and youth mental health, it could become a template for precision psychiatry, in which genomic, proteomic, neuroimaging, and clinical data converge to match young people with the interventions most likely to help them, before patterns of multimorbidity harden into lifelong disability.

The protocol paper itself is a signal as much as a plan. With more than 800 youth already enrolled and three trials in the pipeline, the CALM network is betting that the future of psychiatric research lies not in ever-narrower diagnostic categories but in platforms built to embrace complexity from the start. The next few years of data collection will show whether that bet pays off, but the design choices, dense longitudinal sampling, dual categorical and dimensional assessment, embedded randomization, and deep biological phenotyping, offer one of the most technically complete blueprints yet for studying mental health as young people actually live it.

Subject of Research: A longitudinal master observational trial studying multiple mental health conditions in adolescents and young adults

Article Title: The Cohort network for Adolescents and youth with multipLe Mental health conditions (CALM) Master Observational Trial (MOT): study protocol

Article References: Kimber, M., Vieira, F., Albaum, C., Bray, S., Dickie, E. W., Kozloff, N., Perquier, F., Szatmari, P., Wheeler, A. L., Ameis, S. H., Goldfield, G., Ma, C., Racine, N., Phillips, J. L., Bernier, A., Branje, K., Pathiranawasam, S., Gibson, J., Narajos, A., … Wheeler, A. L. (2026). The Cohort network for Adolescents and youth with multipLe Mental health conditions (CALM) Master Observational Trial (MOT): study protocol. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08492-1

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08492-1

Keywords: adolescent mental health, mental health multimorbidity, master observational trial, cohort study, CALM, youth psychiatry, neuroimaging, genomics, randomized controlled trials, DSM diagnoses, clinical trial design, precision psychiatry